

Cytotoxic Iridoid Aldehydes from Taiwanese *Viburnum luzonicum*

Yoshiyasu FUKUYAMA,^{*,a} Yuka MINOSHIMA,^a Yoshiko KISHIMOTO,^a Ih-Sheng CHEN,^b
Hironobu TAKAHASHI,^a and Tomoyuki ESUMI^a

^aInstitute of Pharmacognosy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University; Yamashiro-cho, Tokushima 770–8514, Japan; and ^bDepartment of Pharmacy, Kaohsiung Medical University; Kaohsiung, 807, Taiwan.

Received August 20, 2004; accepted October 4, 2004

Four new iridoid aldehydes bearing (*E*)- or (*Z*)-*p*-coumaroyl group, luzonial A (1), luzonial B (2), luzonidial A (3), and luzonidial B (4), were isolated from a methanol extract of the dried leaves of *Viburnum luzonicum* collected in Kaohsiung, Taiwan and their structures were elucidated by analysis of spectroscopic data. Compounds 1–3 exhibited moderate inhibitory activity against HeLa S3 cancer cells.

Key words *Viburnum luzonicum*; Caprifoliaceae; iridoid; monoterpenoid; cytotoxicity

We have continued to study vibsane-type diterpenes occurring in *Viburnum awabuki*¹⁾ and *V. odoratissimum*²⁾ from a phytochemical point of view. More than 30 kinds of vibsane-type diterpenes have been found so far, and they can be successfully categorized into three sub-classes.^{3,4)} As part of our studies on biologically active compounds in *Viburnum* species, we have examined chemical components in the leaves of *V. luzonicum*, an evergreen shrub widely distributed in Taiwan. Since one paper reported that a 70% acetone extract of this plant inhibited KB cell growth,⁵⁾ our attention was directed to exploration of the cytotoxic principles, resulting in the isolation of four new iridoid aldehydes 1–4 named luzonials A and B, luzonidials A and B. In this paper, we report the structure elucidation of these new compounds and their inhibitory activity against HeLa S3 cancer cells.

The methanol extract of the leaves of *V. luzonicum* was fractionated on a silica gel column into fractions 1–17. Fractions 3 and 10 were purified by a combination of silica gel chromatography and preparative HPLC, which yielded the four new iridoids 1–4.

Luzonial A (1) had a [M]⁺ ion peak at *m/z* 360.1204 in high-resolution (HR)-EI-MS, corresponding to the molecular formula C₁₉H₂₀O₇ and its IR spectrum displayed absorptions due to the presence of hydroxyl (3338 cm⁻¹) and carbonyl (1683 cm⁻¹) groups, and an aromatic (1587, 1515 cm⁻¹) moiety. The UV (313 nm) and NMR data of 1 (Table 1) showed the presence of an (*E*)-*p*-coumaroyl group [δ 6.80 (2H, d, *J*=8.8 Hz), 7.47 (2H, d, *J*=8.8 Hz), 6.37 (1H, d, *J*=15.9 Hz), 7.64 (1H, d, *J*=15.9 Hz); δ 168.7], which was supported by the observation of prominent fragment peaks at *m/z* 147 and 164 in the EI-MS. The remaining NMR spectral data (Table 1) of 1 indicated the presence of an aldehyde [δ 9.58 (s); δ 196.0] and an *exo*-methylene [δ 6.24 (s), 6.55 (d, *J*=1.1 Hz); δ 134.8, 153.4], which formed a conjugated system on the basis of the correlation of the *exo*-methylene signals with the aldehyde carbonyl in the ¹H-detected heteronuclear multi-bond correlation (HMBC), as well as of an acetal moiety [δ 5.34 (d, *J*=0.8 Hz); δ 104.6] and an isolated oxymethylene [δ 3.93 (d, *J*=9.5 Hz), 4.22 (d, *J*=9.5 Hz); δ 73.5]. The routine analyses of ¹H–¹H shift correlation spectroscopy (COSY) and ¹H-detected heteronuclear correlation through multiple quantum coherence (HMQC) indicated the presence of a partial structure (bold line), as shown in Fig. 2. This partial structure was found to contain the conjugated

exo-methylene aldehyde unit at the C-5 position and the *p*-coumaroyl group at the C-7 position according to the HMBC correlations of H-5 and H-7 resonating at δ 2.99 and 5.22 with the *exo*-methylene carbons C-4 and C-1 and the ester carbonyl of a *p*-coumaroyl group, respectively. In the HMBC as summarized in Fig. 2, the H-10 *oxy*-methylene signals showed correlations with the acetal carbon C-1, whereas the H-1 acetal and H-9 signals had cross peaks to the C-8 quaternary oxygen-bearing carbon at δ 90.7, which further correlated with H-7. These spectral data indicated that C-8 was connected to the *p*-coumaroyl-bearing oxycarbon C-7 and the methine C-9 was involved in the partial unit, and also that C-10 was bonded to C-8 as well as to C-1 through an ether bond, resulting in the formation of an iridoid structure fused with two five-membered rings, as shown in Fig. 1. In addition, stirring a methanol solution of 1 in the presence of Amberlyst 15E gave 1a, which confirmed the presence of a cyclic acetal ring in 1. The relative stereochemistry of 1 was elucidated on the basis of the following nuclear Overhauser and exchange spectroscopy (NOESY) correlations as shown in Fig. 2: H-5/H-9, H-5/H-6 β , H-7/H-10 α , and H-10 β /H-9, which can account for a *p*-coumaroyl group at C-7 and a conjugated aldehyde moiety at C-5 taking a β - and an α -configuration, respectively. However, the configuration on the C-1 acetal carbon was unable to be determined by the NOESY because H-5 observes NOE for H-1 α or H-1 β . The most stable conformation for 1 obtained by a MM2 calculation using Marcromodel[®] indicates that a dihedral angle between H-5 and H-1 α , and H-5 and H-1 β is 82° and 39°, respectively. Considering the small *J* value (0.8 Hz) observed for H-1, the OH located at C-1 should take a β configuration. Accordingly, luzonial A (1) was represented as 1.

Luzonial B (2) was assigned the same molecular formula C₁₉H₂₀O₇ as 1, obtained from HR-EI-MS at *m/z* 360 [M]⁺, and exhibited physical and NMR data (Table 1) very similar to those of compound 1 except for the NMR data assignable to a *p*-coumaroyl group. Namely, a small *J* value (12.6 Hz) was observed for two vicinal olefinic protons, indicating the presence of a (*Z*)-*p*-coumaroyl group. It was also evident from the HMBC correlation of the H-7 signal at δ 5.19 with the ester carbonyl at δ _C 167.8 that this *p*-coumaroyl group was located at the C-7 position. Other NMR data including HMBC and NOESY were consistent with those of 1. Thus the structure of luzonial B (2) was determined to be 7-*O*-(*Z*)-

* To whom correspondence should be addressed. e-mail: fukuyama@ph.bunri-u.ac.jp

Table 1. ^{13}C -NMR (150 MHz) and ^1H -NMR (600 MHz) Spectral Data of Compounds **1** and **2** in CD_3OD

Position	1		2	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}
1	104.6	5.34 d (0.8)	104.7	5.27 d (0.8)
3	196.0	9.58 s	196.0	9.57 s
4	153.4		153.5	
5	39.5	2.99 dddd (7.5, 7.1, 6.9, 1.1)	39.3	2.89 dddd (7.1, 7.1, 6.6, 1.1)
6	36.6	1.99 ddd (13.3, 7.1, 5.9) 2.18 ddd (13.3, 7.5, 5.8)	35.9	1.92 ddd (13.5, 7.1, 6.4) 2.15 ddd (13.5, 7.1, 6.1)
7	82.0	5.22 dd (5.9, 5.8)	81.7	5.19 dd (6.4, 6.1)
8	90.7		90.3	
9	64.4	2.31 dd (6.9, 0.8)	64.0	2.27 dd (6.6, 0.8)
10	73.5	3.93 d (9.5) 4.22 d (9.5)	73.6	3.84 d (9.8) 4.07 d (9.8)
11	134.8	6.24 s 6.55 d (1.1)	134.7	6.23 s 6.54 d (1.1)
Coumaroyl				
1'	168.7		167.8	
2'	114.9	6.37 d (15.9)	116.5	5.81 d (12.6)
3'	147.1	7.64 d (15.9)	145.8	6.91 d (12.6)
4'	127.1		127.7	
5', 9'	131.3	7.47 d (8.8)	133.6	7.61 d (8.4)
6', 8'	116.9	6.80 d (8.8)	115.9	6.75 d (8.4)
7'	161.5		160.2	

All assignments were made by extensive analyses of 1D and 2D NMR (COSY, DEPT, HMQC, and HMBC).



Table 2. Cytotoxic Activities of Compounds **1**–**3** against HeLa S3^(a)

Compound	IC ₅₀ (μM)
1	3.50
2	1.93
3	24.5
4	ND ^(b)
Fluorouracil	5.40
Cisplatin	2.46

a) Human epithelial cancer cell line. b) Not done.

p-coumaroyl derivative of **1**.

Luzonidial A (**3**) had a molecular formula $\text{C}_{19}\text{H}_{18}\text{O}_6$, determined by HR-EI-MS at m/z 342 $[\text{M}]^+$ and its IR spectrum displayed absorptions due to a hydroxyl group at 3368 cm^{-1} , a conjugated carbonyl group at 1680 cm^{-1} , and an aromatic moiety at 1587 and 1515 cm^{-1} . The NMR spectral data of **3** showed the presence of two aldehyde groups [δ 9.85 (s, H-3), 193.5 (C-3); δ 10.1 (s, H-1), 188.3 (C-1)], an exo-methylene [δ 6.03 (s, H-11), 6.15 (d, $J=0.8$ Hz, H-11); δ 134.0 (C-11), 150.3 (C-4)], an isolated oxymethylene [δ 4.38 (d, $J=15.1$ Hz) and 4.85 (d, $J=15.1$ Hz); δ 56.3 (C-10)], and a *p*-coumaroyl group with an *E*-geometry ($J=15.9$ Hz). In addition to these structural fragments, one partial structure, $-\text{C}_{(5)}\text{H}-\text{C}_{(6)}\text{H}_2-\text{C}_{(7)}\text{H}-\text{O}-$, was obtained from analysis of $^1\text{H}-^1\text{H}$ COSY and HMQC. The H-5 signal at δ 4.26 showed not only a long-range coupling (0.8 Hz) to one of the H-11 exo-methylene protons but also HMBC correlations with C-3, C-4, C-11, and two quaternary *sp*² carbons C-8 (δ 158.2) and C-9 (δ 141.5), indicating that C-5 connects to both C-9

Fig. 1. New Iridoids Isolated from *V. luzonicum*Fig. 2. Representative HMBC and NOESY for **1**

and the exo-methylene C-4 bearing an aldehyde group. According to the additional HMBC, the H-7 signal correlated with the C-8 and C-9 resonances, which further had cross-peaks with the H-10 oxy-methylene and the remaining aldehyde H-1 signal, indicating that both C-7 and C-10 link to C-8 and the other aldehyde function bonds to C-9. The *p*-coumaroyl group was confirmed to be located at the C-7 position on the basis of a HMBC correlation between the H-7 signal resonated at δ 6.20 and its ester carbonyl at δ 167.8. Thus, **3** is comprised of a basic iridoid skeleton as shown in Fig. 1. A trans relationship between H-5 and H-7 was elucidated on the basis of the following NOESY: H-5/H-6 β and H-6 α /H-7. The structure of luzonidial A was therefore represented as **3**.

Luzonidial B (**4**) was found to have the same molecular formula $\text{C}_{19}\text{H}_{18}\text{O}_6$ as that of **3**, determined by HR-EI-MS at m/z 342 $[\text{M}]^+$. The spectral data of **4** were similar to those of **3** except for a big difference in the chemical shifts and *J* values corresponding to the coumaroyl H-1' and H-2'. A small $J_{1,2}$ value (12.6 Hz) indicated the double bond geometry for this *p*-coumaroyl to be *Z*. The NOESY experiments indicated that the relative stereochemistry of **4** was the same as that of **3**. Thus the structure of **4** was assigned as a *Z* variant of a *p*-coumaroyl group located at the C-7 position in luzonidial A.

All the new iridoids isolated in this study are structurally analogous to those found in many other species of *Viburnum*.⁶⁾ They are characterized by the presence of (*E*)- or (*Z*)-*p*-coumaroyl group at position 7. Although these iridoids bearing (*E*)- or (*Z*)-*p*-coumaroyl group are readily isolated in a pure form, they gradually interconvert into a mixture of *E* and *Z* at room temperature. In a cytotoxicity assay with the HeLa S3 (human epithelial cancer) cell line, iridoid glucosides (**1**) and (**2**) exhibited moderate inhibitory activity at IC₅₀ values of 1.9–3.5 μM as summarized in Table 2.

Experimental

General Procedure Optical rotations were measured on a JASCO DIP-1000 digital polarimeter. IR spectra were measured on a JASCO FT-IR 5300

infrared spectrophotometer, and 1D- and 2D-NMR spectra were recorded on a Varian Unity 600 instrument. Chemical shifts are given as δ (ppm) with TMS as an internal standard. MS were recorded on a JEOL AX-500 instrument. Column chromatography was carried out on Kieselgel 60 (70–230 mesh) or Wako gel C-300.

Plant Material The leaves of *Viburnum lozonicum* were collected in Kaoshiung, Taiwan in May 2002. Prof. Ih-Sheng Chen identified the plant and a voucher specimen (1714LF) has been deposited at the Institute of Pharmacognosy, TBU.

Extraction and Isolation The dried leaves of *V. luzonicum* (7.0 kg) were extracted with MeOH to yield 800 g of the MeOH extract. The extract (150 g) was chromatographed on a silica gel (Kieselgel 60) column eluting with a step gradient of CH_2Cl_2 (100%), CH_2Cl_2 -EtOAc (9:1), CH_2Cl_2 -EtOAc (3:2), CH_2Cl_2 -EtOAc (2:3), EtOAc (100%), EtOAc-MeOH (9:1), and EtOAc-MeOH (4:1) to give seventeen fractions (fr. 1–17).

Fraction 10 (7.7 g) was first subjected to silica gel (Wako C-300) chromatography eluting with CHCl_3 -EtOAc (1:1) to give fractions 18–27. Fraction 25 (195 mg) was separated by silica gel chromatography with CHCl_3 -MeOH-H₂O (8:2:0.2), followed by reversed-phase HPLC [Cosmosil 5C18-AR-II, ϕ 10 \times 250 mm; H₂O-MeOH (11:9), 2.0 ml/min] to give compounds **1** (6.7 mg) and **2** (3.1 mg). MeOH soluble portion (1.6 g) of fraction 3 (3.7 g) was separated by column chromatography over silica gel eluting with CHCl_3 -EtOAc (1:1) to nine fractions. The eighth fraction (71 mg) was purified by HPLC (Cosmosil 5C18-AR-II, ϕ 10 \times 250 mm) using MeOH-H₂O (11:9, 2.5 ml/min) to give compounds **3** (5.4 mg) and **4** (2.2 mg).

Luzonial A (1): Yellow oil; $[\alpha]_{\text{D}}^{21} -7.1^\circ$ ($c=1.04$, MeOH); IR ν_{max} (film) cm^{-1} : 3338 (OH), 1683 (conj. C=O), 1587, 1515 (aroma.); UV λ_{max} (EtOH) nm: 313 (ϵ 11100), 297 (ϵ 9000), 210 (9300); EI-MS m/z (rel. int.): 360 [$\text{M}]^+$ (2), 164 (100), 147 (89); HR-EI-MS m/z : 360.1204 (M^+ Calcd for $\text{C}_{19}\text{H}_{20}\text{O}_7$; 360.1209); ¹H- and ¹³C-NMR, see Table 1.

Luzonial B (2): Yellow oil; $[\alpha]_{\text{D}}^{21} -1.9^\circ$ ($c=1.17$, MeOH). IR ν_{max} (film) cm^{-1} : 3364 (OH), 1688 (C=O), 1586, 1514 (aroma.); UV λ_{max} (EtOH) nm: 315 (ϵ 10300), 300 (ϵ 8600), 225 (ϵ 9200), 212 (ϵ 10900); EI-MS m/z (rel. int.): 360 [$\text{M}]^+$ (1), 164 (100), 147 (92); HR-EI-MS m/z : 360.1207 (M^+ Calcd for $\text{C}_{19}\text{H}_{20}\text{O}_7$; 360.1209); ¹H- and ¹³C-NMR, see Table 1.

Luzonidial A (3): Yellow oil; $[\alpha]_{\text{D}}^{21} -183.4^\circ$ ($c=0.94$, CHCl_3); IR ν_{max} (film) cm^{-1} : 3368 (OH), 1680 (conj. C=O), 1587, 1515 (aroma.); UV λ_{max} (EtOH) nm: 316 (ϵ 16000), 228 (ϵ 14300); ¹H-NMR (600 MHz, CD_3OD) δ : 2.18 (1H, ddd, $J=14.1, 7.7, 3.8$ Hz, H-6), 2.36 (1H, ddd, $J=14.1, 9.1, 5.1$ Hz, H-6), 4.26 (1H, ddd, $J=9.1, 3.8, 0.8$ Hz, H-5), 4.38 (1H, d, $J=15.1$ Hz, H-10), 4.85 (1H, d, $J=15.1$ Hz, H-10), 6.03 (1H, s, H-11), 6.15 (1H, d, $J=0.8$ Hz, H-11), 6.20 (1H, dd, $J=7.7, 5.1$ Hz, H-7), 6.30 (1H, d, $J=15.9$ Hz, H-2'), 6.86 (2H, d, $J=8.5$ Hz, H-6', 8'), 7.47 (2H, $J=8.5$ Hz, H-5', 9'), 7.69 (1H, $J=15.9$ Hz, H-3'), 9.85 (1H, s, H-3), 10.1 (1H, s, H-1); ¹³C-NMR (150 MHz, CD_3OD) δ : 36.6 (C-6), 40.9 (C-2), 56.3 (C-10), 78.6 (C-7), 114.1 (C-2'), 116.0 (C-6', 8'), 126.8 (C-4'), 130.3 (C-5', 9'), 134.0 (C-11), 141.5 (C-9), 146.3 (C-3'), 150.3 (C-4), 158.1 (C-7'), 158.2 (C-8), 167.8 (C-1'), 188.3 (C-1), 193.5 (C-3); EI-MS m/z (rel. int.): 342 [$\text{M}]^+$, 147 (100); HR-EI-MS m/z : 342.1118 (M^+ Calcd for $\text{C}_{19}\text{H}_{18}\text{O}_6$; 342.1103).

Luzonidial B (4): Yellow oil; $[\alpha]_{\text{D}}^{21} -32.4^\circ$ ($c=0.54$, CHCl_3); IR (film) ν_{max} (film) cm^{-1} : 3400 (OH), 1682 (conj. C=O), 1604, 1514; ¹H-NMR (600 MHz, CD_3OD) δ : 2.14 (1H, ddd, $J=14.1, 7.6, 4.3$ Hz, H-6), 2.24 (1H, ddd, $J=14.1, 9.1, 4.9$ Hz, H-6), 4.17 (1H, ddd, $J=9.1, 4.3, 0.8$ Hz, H-5), 4.36 (1H, d, $J=15.1$ Hz, H-10), 4.78 (1H, d, $J=15.1$ Hz, H-10), 5.84 (1H, d, $J=12.6$ Hz, H-2'), 6.03 (1H, s, H-11), 6.09 (1H, dd, $J=7.6, 4.9$ Hz, H-7), 6.13 (1H, d, $J=0.8$ Hz, H-11), 6.83 (2H, d, $J=8.5$ Hz, H-6', 8'), 6.96 (1H, d,

$J=12.6$ Hz, H-3'), 7.62 (2H, d, $J=8.5$ Hz, H-5', 9'), 9.55 (1H, s, H-3), 10.1 (1H, s, H-1); ¹³C-NMR (150 MHz, CD_3OD) δ : 36.7 (C-6), 41.0 (C-5), 56.6 (C-10), 78.9 (C-7), 115.1 (C-6', 8'), 116.0 (C-2'), 127.2 (C-4'), 131.1 (C-11), 132.5 (C-5', 9'), 141.5 (C-9, C-1'), 145.7 (C-3'), 150.2 (C-4), 157.0 (C-7'), 158.0 (C-8), 188.4 (C-1), 193.5 (C-3); EI-MS m/z (rel. int.): 342 [$\text{M}]^+$, 147 (100); HR-EI-MS m/z : 342.1118 (M^+ Calcd for $\text{C}_{19}\text{H}_{18}\text{O}_6$; 342.1103).

Methylation of 1 A mixture of **1** (2 mg) and Amberlyst 15E (2 pieces) in MeOH (1 ml) was stirred for 12 h at room temperature. After the catalyst was filtered, the filtrate was condensed *in vacuo* to give **1a** (2.1 mg) as yellow oil. $[\alpha]_{\text{D}}^{21} -23.3^\circ$ ($c=0.62$, MeOH); IR ν_{max} (film) cm^{-1} : 3350 (OH), 1689 (C=O), 1586, 1515 (aroma.); UV λ_{max} nm (ϵ): 315 (14800), 298 (11800), 215 (14400); ¹H-NMR (600 MHz, CDCl_3) δ : 2.12 (1H, ddd, $J=13.5, 7.1, 4.4$ Hz, H-6), 2.16 (1H, ddd, $J=13.5, 9.1, 8.7$ Hz, H-6), 2.50 (1H, d, $J=4.7$ Hz, H-9), 3.06 (1H, dddd, $J=8.7, 4.7, 4.4, 1.1$ Hz, H-5), 3.37 (3H, s, OMe), 3.70 (1H, s, 8-OH), 3.84 (1H, d, $J=9.9$ Hz, H-10), 4.22 (1H, d, $J=9.9$ Hz, H-10), 4.92 (1H, s, H-1), 5.20 (1H, dd, $J=9.1, 7.1$ Hz, H-7), 6.17 (1H, s, H-11), 6.33 (1H, d, $J=15.9$ Hz, H-2'), 6.59 (1H, d, $J=1.1$ Hz, H-11), 6.85 (2H, d, $J=8.5$ Hz, H-6', 8'), 7.45 (2H, $J=8.5$ Hz, H-5', 9'), 7.66 (1H, $J=15.9$ Hz, H-3'), 9.58 (1H, s, H-3); ¹³C-NMR (150 MHz, CDCl_3) δ : 34.7 (C-6), 36.7 (C-5), 54.6 (OCH₃), 60.9 (C-9), 73.4 (C-10), 82.1 (C-7), 88.7 (C-8), 110.4 (C-1), 114.4 (C-2'), 115.9 (C-6', 8'), 127.0 (C-4'), 130.3 (C-5', 9'), 134.2 (C-11), 146.0 (C-3'), 151.8 (C-4), 157.9 (C-7'), 168.2 (C-1'), 194.0 (C-3); EI-MS m/z (rel. int.): 374 [$\text{M}]^+$ (4), 343 (2), 147 (100); HR-EI-MS m/z : 374.1357 (M^+ Calcd for $\text{C}_{20}\text{H}_{22}\text{O}_7$; 374.1366).

Cell Proliferation Assay Cell proliferation assay was carried out using a Cell Counting Kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan). In brief, HeLa S3 cells were plated in 384-well plates at a density of 500 cells/well in minimum essential medium. Following overnight culture, drugs were added to final concentrations of 0.1, 1, 10, and 100 μM , and the cells were incubated for 72 h. After 72 h, WST-1 was added according to the manufacturer's protocol and the cells were further incubated for 2 h. The plates were read at a wavelength of 450 nm using a Microplate Reader Wallac 1420 ARVosx (Perkin Elmer Life and Analytical Sciences, Inc., Boston, MA, U.S.A.). The assay results are summarized in Table 2.

Acknowledgements We would like to thank Dr. Masami Tanaka and Miss Yasuko Okamoto for measuring NMR and mass spectra, and Dr. Hiroaki Tsujimoto, Taiho Pharmaceutical Co., Ltd., for conducting a cytotoxicity assay. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (16510172), and the Open Research Center Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan.

References

- 1) Fukuyama Y., Morisaki M., Minoshima Y., Minami H., Takahashi H., Asakawa Y., *Lett. Org. Chem.*, **1**, 189–193 (2004).
- 2) Kubo M., Chen I.-S., Minami H., Fukuyama Y., *Chem. Pharm. Bull.*, **49**, 242–245 (2001).
- 3) Fukuyama Y., Minami H., Takaoka S., Kodama M., Kawazu K., Nemoto H., *Tetrahedron Lett.*, **38**, 1435–1438 (1997).
- 4) Fukuyama Y., Kubo M., Fujii T., Matsuo A., Minoshima Y., Minami H., Morisaki M., *Tetrahedron*, **58**, 10033–10041 (2002).
- 5) Wang C.-C., Chen H.-L., Yang, L.-L., *Taiwan Kexue*, **51**, 1–18 (1998).
- 6) Iwagawa T., Yaguchi S., Hase T., *Phytochemistry*, **29**, 310–312 (1990).